GLP-1 Drugs and Kidney Disease

Join host Julia Cartwright as she explores how GLP-1 drugs—best known for weight loss and diabetes—are emerging as unexpected protectors of kidney health. Through landmark trials and cutting-edge research, Julia breaks down the science in plain language, revealing who could benefit most from this promising development. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Join host Julia Cartwright as she explores who benefits most from GLP-1 receptor agonists in kidney disease treatment. From the groundbreaking FLOW trial results in diabetic patients to emerging research in non-diabetic kidney disease, discover what four pillars of modern kidney care mean for patients facing declining function, and what cutting-edge biopsy studies reveal about these medications' future potential. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Julia Cartwright explores how GLP-1 drugs protect kidneys through multiple pathways—reducing inflammation, scarring, and protein leakage while improving blood sugar and blood pressure. Research shows these medications lower kidney failure risk by 16% in diabetic and non-diabetic patients, offering hope beyond traditional treatments as a promising fourth pillar of kidney disease prevention. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Julia Cartwright explores how the FLOW trial revealed GLP-1 drugs like semaglutide offer groundbreaking kidney protection for diabetic patients, reducing kidney failure risk by 24%—results so powerful the study stopped early, establishing a fourth pillar in chronic kidney disease treatment alongside existing therapies. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.